CTOs on the Move

UT Medical Group

www.utmedicalgroup.com

 
UT Medical Group is the private practice arm of the University of Tennessee Health Science Center (UTHSC) faculty. Because the physicians in our group are actively involved in teaching and research, they remain current with the latest medical developments. As a not-for-profit, non-tax-supported group practice, UT Medical Group is dedicated to quality patient care, medical education, and medical research. This allows us to offer many unique, advanced health care services to people in the Mid-South at competitive prices. Ties to UTHSC allow the physicians at UT Medical Group access to the latest treatments, special protocols and labs, as well as a broad ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

MedPoint Digital

MedPoint is focused on innovative, high-value services. We are a global best-in-class company in our service areas. We work with clients on new approaches to training, education and communications that work in the real world of medicine.

Nexus Communications

Nexus Communications is a North Wales, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Institute for Healthcare Communication

Institute for Healthcare Communication is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

VTS Medical Systems

VTS Medical Systems is a Melville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Versartis

Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.